Being Specific About Race-Specific Medicine

3 Pages Posted: 30 Aug 2006

See all articles by Jonathan D. Kahn

Jonathan D. Kahn

Northeastern University - School of Law; Northeastern University - Center for Law, Innovation and Creativity

Pamela Sankar

University of Pennsylvania - Perelman School of Medicine

Abstract

This article is a response to Gary Puckrein's paper "BiDil: From Another Vantage Point," which misrepresents rather than refutes our previously published analysis of BiDil. Puckrein claims that if our analysis were to prevail, patients would be denied life-saving therapy. Any reasonable reading of our paper suggests exactly the opposite. Indeed, based on the evidence, we urge doctors to prescribe the generics or BiDil itself as they see fit, but without regard to the race of their patient.

Keywords: Business of Health, Consumer Issues, Demography, Ethical Issues, Legal/Regulatory Issues, Minority Health, Pharmaceuticals

JEL Classification: D40, I11, I18, K10, K23, L65

Suggested Citation

Kahn, Jonathan D. and Sankar, Pamela, Being Specific About Race-Specific Medicine. Health Affairs, Vol. 25, 2006, Available at SSRN: https://ssrn.com/abstract=927441

Jonathan D. Kahn (Contact Author)

Northeastern University - School of Law ( email )

416 Huntington Avenue
Boston, MA 02115
United States

Northeastern University - Center for Law, Innovation and Creativity

416 Huntington Avenue
Boston, MA 02115
United States

Pamela Sankar

University of Pennsylvania - Perelman School of Medicine ( email )

423 Guardian Drive
Philadelphia, PA 19104
United States

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
151
Abstract Views
1,522
rank
229,738
PlumX Metrics